10 August 2015
Being a player in a space as competitive as transcatheter aortic valve replacement (TAVR) takes some serious financial backing. Jenavalve Technology (Irvine, Calif.) has risen to that challenge multiple times, most recently with a $26.5 million Series C expansion round to support its growth in the global TAVR market.
4 August 2015
JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical technology financial executive Peter C. Wulff as Chief Financial Officer (CFO), effective immediately. Mr. Wulff will be based in Irvine, Calif. at JenaValve’s new corporate headquarters. “
30 July 2015Genkyotex’s NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results
Research Conducted by Leading Academic Labs Further Elucidates Fundamental Role of NOX Enzymes in Fibrosi
Genkyotex, the leading developer of selective NOX inhibitors, announced today publication of results from two independent studies confirming the important role played by both NOX1 and NOX4 enzymes in the development of liver fibrosis. This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such as nonalcoholic steatohepatitis (NASH). Genkyotex’s lead inhibitor, GKT137831, is in a Ph2 trial in diabetic nephropathy, the data from which is also being analyzed to support the company’s plan to evaluate the drug in a range of fibrotic diseases.
22 July 2015
Wilson Therapeutics AB, a privately-held biopharmaceutical company developing novel treatments for patients with Wilson’s Disease, today announced the appointment of Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will report to Jonas Hansson, chief executive officer, and will join the company’s management team.
9 July 2015
InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.